Prab: CSV import

2024-03-06T07:03:07Z

CSV import

New page

[[File:BOLD-100.svg|thumb|{{PAGENAME}}]]<br>'''BOLD-100''' is an experimental [[cancer]] [[drug]] currently under development. It is a first-in-class ruthenium-based small molecule that selectively inhibits stress-induced upregulation of [[GRP78]], a protective chaperone protein that is overexpressed in many types of cancer.

== Mechanism of Action ==

BOLD-100's mechanism of action involves the selective inhibition of [[GRP78]], a master regulator of the [[unfolded protein response]] (UPR). The UPR is a cellular stress response related to the [[endoplasmic reticulum]] (ER). In many types of cancer, the UPR is chronically activated, leading to overexpression of GRP78. By inhibiting GRP78, BOLD-100 disrupts the UPR, leading to cell death in cancer cells.

== Clinical Development ==

BOLD-100 is currently in [[clinical trials]] for the treatment of various types of cancer. Early phase trials have shown promising results, with evidence of efficacy and a favorable safety profile. The drug is being developed by [[Bold Therapeutics]], a clinical-stage biopharmaceutical company.

== Potential Applications ==

In addition to its potential as a standalone cancer treatment, BOLD-100 may also have applications in combination therapy. Preclinical studies have shown that it can enhance the efficacy of other cancer drugs, including [[chemotherapy]] agents and [[immunotherapy]] drugs.

== See Also ==

* [[GRP78]]
* [[Unfolded protein response]]
* [[Endoplasmic reticulum]]
* [[Clinical trial]]
* [[Bold Therapeutics]]
* [[Chemotherapy]]
* [[Immunotherapy]]

[[Category:Experimental cancer drugs]]
[[Category:Pharmacology]]
{{Pharmacology-stub}}

BOLD-100 - Revision history

Prab: CSV import